AnaptysBio trumpeted a Phase 2b success in rheumatoid arthritis Wednesday morning after a similar program from Eli Lilly was discontinued late last year.

Ab­b­Vie and Xilio Ther­a­peu­tics are part­ner­ing to make “masked” T cell en­gagers, which they hope will be safer than cur­rent­ly avail­able op­tions.

Odyssey layoffs, GSK relocates vaccine R&D, Aligos raises $105M, Terrain Bio launches, Gates Foundation backs antibiotics research, Neuphoria gets Merck milestone ...

After quickly enrolling its pivotal trial and recruiting more patients with a rare muscle disease than anticipated, Abcuro ...

Biogen is turning to Royalty Pharma for some cash in exchange for rights to a lupus program, the companies announced ...

CMO Dietmar Berger leads Gilead's R&D efforts with 54 clinical programs, anticipating Sunlenca's HIV PrEP launch & touting no ...

Spring­Works Ther­a­peu­tics, a biotech po­ten­tial­ly on the verge of be­ing ac­quired, won its sec­ond FDA ap­proval. Get ...

Travere Therapeutics said Tuesday it plans to ask the FDA for approval of its kidney drug Filspari in a rare condition known ...

FDA grants priority review for Biohaven's troriluzole for spinocerebellar ataxia after real-world data submission. Decision ...

Chinese API manufacturers Wuhu Nuowei Chemistry and Chengdu Innovation Pharmaceutical have been placed on US import alert ...

Health acquires Caraway Health, merging pediatric urgent care with Gen Z virtual care. The deal is another tying together two ...

Major pharma firms like Eli Lilly, GSK, Merck, Regeneron and Sanofi announce $35B+ in share buybacks since December, ...